Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Recs

2
Player Avatar stockfreak1 (< 20) Submitted: 7/23/2010 11:28:50 PM : Underperform Start Price: $16.60 GILD Score: -364.45

With more and more HIV generics around the corner it's not surprising why the CEO is selling and selling quick. Anyone actually see the retail prices on their drugs? Good God Viread is like $12 a pill. This is a friendly reminder to wear a condom. Hey, I think this company has great innovation and cash flow, but their eggs are all in one basket.

Member Avatar BUbulldog (63.25) Submitted: 1/8/2014 1:17:49 PM
Recs: 0

I know this pitch is outdated, but scoffing at $12 a pill? The new Hep C drug (oral treatment) costs $28,000 for the first four weeks. As for "eggs in one basket", the company has several treatments aimed at things other than HIV. If considering shorting the company, I wouldn't use this post as my rationale.

Featured Broker Partners


Advertisement